Papillomavirus Vaccines Clinical Trial
Official title:
Complementary Testing to Further Evaluate the Immunogenicity of a GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Aged Over 26 Years Enrolled in Study 104820.
Infection with human papillomavirus (HPV) has been clearly established as the central cause
of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of
the uterus or womb). This infection may go away by itself, but if it does not go away (this
is called persistent infection), it can lead in women over a long period of time to cancer
of the cervix. This study will supplement an ongoing study evaluating the safety, efficacy
and immunogenicity of the vaccine in women aged 26 years and above. This study will
therefore assess additional immunogenicity parameters of the vaccine in women from selected
investigative sites.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
2007.
Status | Completed |
Enrollment | 100 |
Est. completion date | January 2008 |
Est. primary completion date | January 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 26 Years and older |
Eligibility |
Inclusion Criteria: - A female enrolled in study 104820 and who received three doses of study vaccine/control. - Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. - Written informed consent obtained from the subject prior to enrolment in this ancillary study. Exclusion Criteria: - Pregnancy. - Administration of any HPV vaccine other than that foreseen by the study protocol. - Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine since study start. - Chronic administration of immunosuppressants or other immune-modifying drugs since study start. - Administration of immunoglobulins and/or any blood products within 90 days preceding a blood sampling. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Netherlands | GSK Investigational Site | Amsterdam | |
Netherlands | GSK Investigational Site | Delft |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Cytokine-positive CD4/CD8 Cells Per Million in Tests Producing at Least 2 Different Cytokines | The geometric mean and 95% confidence interval of the number of Human Papilloma Virus type 16 (HPV-16) and HPV-18 specific CD4 and CD8 cells producing at least 2 different cytokines is reported per million of CD4 or CD8 T-cells, respectively. | At Month 12 and Month 18 after first vaccination | No |
Primary | Number of B-cells Per Million Showing a Specific Memory Response for HPV-16 and HPV-18 | The geometric mean and 95% confidence interval of the number of HPV-16 and HPV-18 specific memory B-cells is reported per million of B-cells. An arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification. |
At Month 12 and Month 18 after first vaccination | No |
Primary | Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations Above Pre-defined Cut-off Values | Cut-off values assessed include 8 enzyme-linked immunosorbent assay units Per Milliliter (EL.U/mL)for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies. | At Month 12 and Month 18 after first vaccination | No |
Primary | Titers of Anti-HPV-16 and Anti-HPV-18 Antibodies | Titers are presented as Geometric Mean Titers (GMTs). | At Month 12 and Month 18 after first vaccination | No |
Primary | Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) Immunoglobulin G (IgG) Antibodies | Titers given as Geometric Mean Titers (GMTs). An arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification. | At Month 12 and Month 18 after first vaccination | No |
Primary | Correlation of Anti-HPV-16 and Anti-HPV-18 Antibodies in Serum and in Cervical Secretion (CVS) Samples | Pearson coefficients of correlation between serum and CVS for anti-HPV-16 and anti-HPV-18 titers standardized for total IgG were calculated. | At Month 12 and Month 18 after first vaccination | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00359619 -
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
|
Phase 2 | |
Completed |
NCT00250276 -
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
|
Phase 3 | |
Completed |
NCT01031069 -
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
|
Phase 4 | |
Recruiting |
NCT05266898 -
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
|
Phase 4 | |
Completed |
NCT03763565 -
Effectiveness of HPV Vaccine in Thai Adult Women
|
||
Completed |
NCT00877877 -
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
|
Phase 3 | |
Completed |
NCT00811798 -
Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.
|
Phase 3 | |
Recruiting |
NCT05884697 -
Let's K-Talk - HPV Study for Ethnic Koreans
|
N/A | |
Completed |
NCT00637195 -
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
|
Phase 3 | |
Completed |
NCT00798265 -
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
|
Phase 1 | |
Completed |
NCT00423046 -
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
|
Phase 3 | |
Completed |
NCT00294047 -
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
|
Phase 3 | |
Recruiting |
NCT04469569 -
Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors
|
N/A | |
Not yet recruiting |
NCT04671823 -
Changes in the Prevalence of Oncogenic HPV Types
|
||
Active, not recruiting |
NCT05148559 -
Impact of Adolescent Vaccine Reminder Notices Sent Via Preferred Method of Communication on HPV Vaccination
|
N/A | |
Recruiting |
NCT03350698 -
Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination
|
Phase 4 | |
Completed |
NCT02370459 -
AFIX to Improve HPV Vaccination
|
N/A | |
Completed |
NCT03501992 -
Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination
|
N/A |